Roche gets EMA rec­om­men­da­tion for Ocre­vus; An­them now cov­ers Sarep­ta's ex­on-skip­ping Duchenne MD drug

→ The EMA’s Com­mit­tee for Med­i­c­i­nal Prod­ucts for Hu­man Use has giv­en a glow­ing rec­om­men­da­tion for Roche’s mul­ti­ple scle­ro­sis drug Ocre­vus (ocre­lizum­ab), paving the way for mar­ket­ing au­tho­riza­tion in the EU. The brief an­nounce­ment, which comes eight months af­ter the FDA ap­proval, notes that Ocre­vus is the “first med­i­cine to re­ceive pos­i­tive opin­ion for treat­ment of pa­tients with ear­ly stage of pri­ma­ry pro­gres­sive mul­ti­ple scle­ro­sis.” With a larg­er reach than its (many) com­peti­tors, the drug has been tout­ed as a po­ten­tial game chang­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER